CONTINUOUS VS 24 WK COURSES OF INTRON A THERAPY FOR RELAPSED HEPATITIS C

内含子 A 治疗复发性丙型肝炎的连续疗程与 24 周疗程比较

• 批准号: 6118111
• 负责人: John G. McHutchison
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118111
• 关键词: antiviral agents; chronic disease /disorder; clinical research; drug administration rate /duration; drug screening /evaluation; hepatitis C; human subject; human therapy evaluation; interferon alpha; longitudinal human study

This study addresses the efficacy of interferon alpha-2b (continuation of treatment >6 months) for patients who responded to a previous treatment then relapsed with chronic hepatitis C virus (HCV) infection. The biochemical and virological response to treatment are measured at two time points: at the end of treatment and six months post treatment sustained response. Based on these markers, this continuing randomized clinical trial has preliminarily demonstrated that treatment with interferon alpha-2b benefits some previously treated HCV patients. Current studies focus on treatment approaches using drugs in combination with interferon to possibly enhance a sustained response.

本研究探讨了干扰素 α-2b（持续治疗 >6 个月）对先前治疗有反应但因慢性丙型肝炎病毒 (HCV) 感染复发的患者的疗效。 在两个时间点测量对治疗的生化和病毒学反应：治疗结束时和治疗后六个月持续反应。 基于这些标志物，这项持续的随机临床试验初步证明，干扰素α-2b治疗对一些先前接受过治疗的HCV患者有益。 目前的研究重点是使用药物与干扰素联合使用的治疗方法，以可能增强持续反应。